TY - JOUR AU - Sanchez-Luna, M. AU - Burgos-Pol, R. AU - Oyagüez, I. AU - Figueras-Aloy, J. AU - Sánchez-Solís, M. AU - Martinón-Torres, F. AU - Carbonell-Estrany, X. PY - 2017 DA - 2017/10/17 TI - Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain JO - BMC Infectious Diseases SP - 687 VL - 17 IS - 1 AB - This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age –wGA-) in Spain. SN - 1471-2334 UR - https://doi.org/10.1186/s12879-017-2803-0 DO - 10.1186/s12879-017-2803-0 ID - Sanchez-Luna2017 ER -